Clinical Trials Browser

Phase 2 × Completed × ponatinib × Clear all

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03690115 2025-03-25

PONALLO

Phase 2 Completed

23 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02272998 2025-03-24

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Phase 2 Completed

22 enrolled 13 charts

Neoplasms, Piebaldism

NCT01935336 2022-02-11

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Phase 2 Completed

171 enrolled 13 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT01641107 2021-11-30

LAL1811

Phase 2 Completed

44 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01207440 2021-02-02

PACE

Phase 2 Completed

449 enrolled 28 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02265341 2020-11-25

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Phase 2 Completed

12 enrolled 11 charts

Gastrointestinal

Malignant Hepatobiliary Neoplasm

NCT01813734 2019-12-24

Ponatinib in Advanced NSCLC w/ RET Translocations

Phase 2 Completed

9 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02478164 2018-07-24

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Phase 2 Completed

17 enrolled 13 charts

CNS

Glioblastoma

NCT01874665 2018-05-18

GIST

Phase 2 Completed

45 enrolled 21 charts

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Clinical Trials

OPTIC

PONALLO

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

LAL1811

PACE

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Ponatinib in Advanced NSCLC w/ RET Translocations

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

GIST